Pipeline

A pipeline innovated by the global human crisis

Indivior is pioneering the development and discovery of non-opioid treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders. 

Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients. 

Indivior’s quarterly R&D and pipeline update can be found here.

 

Compound Name

Preclinical

Phase 1

Phase 2

Phase 3

Regulatory Approval or Review

 
 
 
 
 
 
  • Treatment for Substance Use Disorder

    INDV-3000 - Selective Dopamine D3-receptor Antagonist

  • Treatment for Substance Use Disorder

    INDV-10001 - GABA-B Positive Allosteric Modulator

  • Treatment for Substance Use Disorder

    INDV-20002 - Selective Orexin-1 Receptor Antagonist

  • Treatment for Cannabis Use Disorder

    AEF01173 - Synthetic Signaling Specific inhibitor (SSi) of the Cannabinoid Type 1 (CB1) Receptor

  • Treatment for Opioid Use Disorder

    RBP-6000 - Buprenorphine XR injection for Subcutaneous Use

  • Treatment for Schizophrenia

    RBP-70004 - Risperidone XR injection for Subcutaneous Use

  • Treatment for Opioid Use Disorder

    Buprenorphine/ Naloxone Sublingual Film

  • Treatment for Opioid Use Disorder

    Buprenorphine/ Naloxone Sublingual Tablet

  • Treatment for Opioid Use Disorder

    Buprenorphine Sublingual Tablet

  1. Partnership with Addex Therapeutics
  2. Partnership with C4X Discovery Holdings
  3. Partnership with Aelis Farma
  4. Partnership with HLS in Canada

Pipeline Disclaimer: The information included on this site reflects Indivior’s research and development pipeline and is not intended for promotional purposes. Information is current as of July 30, 2021.

 

Related Content